This biggest success of Week 2 was attending a happy hour networking event completely sober. I headed there with a friend who was also doing Whole30, and we vowed to be each other's support system. We ordered seltzer waters together and proudly said no to the cheeseburger sliders and cheese board. Leaving the event, I felt empowered knowing I had it in me to refuse alcohol and fatty food, something I'd never tried before. Plus, I now knew I didn't have to use alcohol as a social crutch.
Glassman grew up in Woodland Hills, a suburb of Los Angeles in the San Fernando Valley. In the Glassman household, education trumped everything. Glassman's father was a rocket scientist at Hughes Aircraft and an all-around hard-ass who lorded math and the scientific method over Glassman, his younger sister, and their stay-at-home mom. Arguments with the old man inevitably required data sets, says Glassman--"Any point you made had to be measurable, repeatable"--and Glassman clashed with his dad frequently.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”